343 related articles for article (PubMed ID: 37398672)
1. PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma.
Song F; Wang CG; Mao JZ; Wang TL; Liang XL; Hu CW; Zhang Y; Han L; Chen Z
Front Immunol; 2023; 14():1197152. PubMed ID: 37398672
[TBL] [Abstract][Full Text] [Related]
2. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
3. Robust analysis of a novel PANoptosis-related prognostic gene signature model for hepatocellular carcinoma immune infiltration and therapeutic response.
Wei Y; Lan C; Yang C; Liao X; Zhou X; Huang X; Xie H; Zhu G; Peng T
Sci Rep; 2023 Sep; 13(1):14519. PubMed ID: 37666920
[TBL] [Abstract][Full Text] [Related]
4. Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma.
Zhang L; Xu J; Chu X; Zhang H; Yao X; Zhang J; Guo Y
BMC Bioinformatics; 2022 Nov; 23(1):485. PubMed ID: 36384423
[TBL] [Abstract][Full Text] [Related]
5. A novel PANoptosis-related long non-coding RNA index to predict prognosis, immune microenvironment and personalised treatment in hepatocellular carcinoma.
Wang L; Wan P; Xu Z
Aging (Albany NY); 2024 Jan; 16(3):2410-2437. PubMed ID: 38284890
[TBL] [Abstract][Full Text] [Related]
6. Characteristic of molecular subtypes based on PANoptosis-related genes and experimental verification of hepatocellular carcinoma.
Ren H; Kang N; Yin S; Xu C; Qu T; Dai D
Aging (Albany NY); 2023 May; 15(10):4159-4181. PubMed ID: 37171396
[TBL] [Abstract][Full Text] [Related]
7. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
Xiong X; Song Q; Jing M; Yan W
Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
[TBL] [Abstract][Full Text] [Related]
8. Immunogenic landscape and risk score prediction based on unfolded protein response (UPR)-related molecular subtypes in hepatocellular carcinoma.
Guo H; Zhang S; Zhang B; Shang Y; Liu X; Wang M; Wang H; Fan Y; Tan K
Front Immunol; 2023; 14():1202324. PubMed ID: 37457742
[TBL] [Abstract][Full Text] [Related]
9. Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma.
Shi X; Gao X; Liu W; Tang X; Liu J; Pan D; Duan X; Jin Y; Ren W; Yang L; Liu W
Oncol Res; 2023; 31(4):569-590. PubMed ID: 37415742
[TBL] [Abstract][Full Text] [Related]
10. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
11. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
12. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
13. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
14. Integrated investigation of the clinical implications and targeted landscape for RNA methylation modifications in hepatocellular carcinoma.
Zhang J; Gao J; Hu M; Xu S; Cheng C; Zheng W; Zhang J
Eur J Med Res; 2023 Jan; 28(1):46. PubMed ID: 36707911
[TBL] [Abstract][Full Text] [Related]
15. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma.
Lin H; Zhang R; Wu W; Lei L
Cancer Genet; 2020 Jul; 245():27-34. PubMed ID: 32559715
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
Wang L; Wang L; He P
Front Genet; 2022; 13():1064432. PubMed ID: 36568383
[No Abstract] [Full Text] [Related]
18. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
19. Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs.
He M; Gu W; Gao Y; Liu Y; Liu J; Li Z
Front Immunol; 2022; 13():1043827. PubMed ID: 36479122
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma.
Ma P; Zou C; Xia S
Immunogenetics; 2022 Dec; 74(6):539-557. PubMed ID: 35895154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
